Taiwan study reveals HER2 rates in Tough-to-Treat gynecologic cancers
NCT ID NCT06925113
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 32 times
Summary
This study looked at medical records from 509 adults in Taiwan to find out how often a protein called HER2 IHC 3+ appears in advanced endometrial, ovarian, and cervical cancers. The goal was to better understand these cancers and help guide future treatment options. No new treatments were tested—only existing data was reviewed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, 833, Taiwan
-
Mackay Memorial Hospital
Taipei, 104, Taiwan
-
National Taiwan University Hospital
Taipei, 100, Taiwan
-
Taichung Veterans General Hospital
Taichung, 407, Taiwan
-
Taipei Veterans General Hospital
Taipei, 112, Taiwan
Conditions
Explore the condition pages connected to this study.